No Data
Wai Chun Bio-Technology to Vote April 30 on Capital Reorganization
WAI CHUN BIOTEC: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 30 JUNE 2024
Wai Chun Bio-Technology 2024 Loss Widens Considerably
WAI CHUN BIOTEC (00660.HK) reported mid-term revenue of approximately 0.161 billion HKD, a year-on-year decrease of 15.4%.
On February 28, Gelonghui announced that WAI CHUN BIOTEC (00660.HK) recorded revenue of approximately HKD 161,056,000 for the six months ended December 31, 2024, a decrease of 15.4% year-on-year. The decline in revenue was due to a reduction in Consumer market consumption and demand during the period. The loss attributable to shareholders was approximately HKD 13,661,000, compared to a loss of approximately HKD 6,734,000 in the same period last year. The increase in losses attributable to shareholders was mainly due to impairment losses on receivables and other receivables recognized during the review period, as well as depreciation of properties, plants, and equipment.
WAI CHUN BIOTEC: INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2024
WAI CHUN BIOTEC: Annual Report 2023/24
